E STROGENS ARE INVOLVED in numerous physiological
processes including the development and maintenance of the female sexual organs, the reproductive cycle, reproduction, and various neuroendocrine functions. These hormones also have crucial roles in certain disease states, particularly in mammary and endometrial carcinomas. Cancer is the leading cause of death among women between the ages of 30 and 54, with breast and uterine cancers comprising 28% and 10%, respectively, of all cancers in females per year. An estimated 217,440 new cases of breast cancer will be diagnosed, and 40,580 women in the United States were projected to die from breast cancer in 2004 (1) . Currently, one of eight American women will develop breast cancer in her lifetime. Approximately two thirds of postmenopausal breast cancer patients have hormone-dependent (estrogen-dependent) breast cancer, which contains estrogen receptors and requires estrogen for tumor growth. Estrogens produce normal physiological effects by binding to specific nuclear receptor proteins, estrogen receptor-␣ and estrogen receptor-␤ (2). The predominant estrogen receptor in the female reproductive tract and mammary glands is estrogen receptor-␣. Following the binding of estrogen to its receptor, the estrogenreceptor complexes form homodimers and interact with sequence-specific estrogen response elements present in the promoter region of responsive genes in target cell chromatin. Binding of the nuclear steroid-receptor complexes to DNA and interaction with various nuclear transcriptional factors, such as steroid receptor coactivator proteins, initiate the transcription of the relevant gene to produce mRNA. The elevated mRNA levels result in increased protein synthesis in the endoplasmic reticulum. These proteins include enzymes, receptors, and secreted factors that subsequently result in the steroid hormonal response regulating cell function, growth, and differentiation. Estrogens enhance growth and proliferation of certain target cells, such as breast epithelial cells and estrogen-dependent mammary carcinoma cells, and induce the formation and secretion of various growth factors in established cell lines such as MCF-7, T47D, and ZR-75-1 human mammary carcinoma lines (3) .
II. Aromatase and Estrogen Biosynthesis
A. Biochemistry of aromatase P450 enzyme complex called "aromatase" (4) , with the highest levels of enzyme present in the ovaries of premenopausal women, in the placenta of pregnant women, and in the peripheral adipose tissues of postmenopausal women and of men. Aromatase activity has also been demonstrated in breast tissue in vitro (5) (6) (7) . Furthermore, expression of aromatase is highest in or near breast tumor sites (6, 8) .
The enzyme complex is bound in the endoplasmic reticulum of the cell and is comprised of two major proteins (4, 9) . One protein is cytochrome P450 arom , a hemoprotein that converts C 19 steroids (androgens) into C 18 steroids (estrogens) containing a phenolic A ring (4, 10) . The second protein is NADPH-cytochrome P450 reductase, which transfers reducing equivalents to cytochrome P450 arom. Three moles of NADPH and three moles of oxygen are used in the conversion of one mole of substrate into one mole of estrogen product (Fig. 1) . Aromatization of androstenedione, the preferred substrate, proceeds via three successive oxidation steps, with the first two being hydroxylations of the angular C-19 methyl group. The final oxidation step proceeds with the aromatization of the A ring of the steroid and loss of the C-19 carbon atom as formic acid.
This third and final step in the aromatase reaction oxidatively cleaves the C 10 -C 19 bond, although the mechanism of this step remains to be elucidated. A number of mechanisms have been proposed, and one mechanism for the oxidative deformylation step that has received significant favor involves nucleophilic attack of the 19-aldehyde by the reduced ferrous dioxygen, or peroxy, intermediate ( Fig. 2A) . The resulting peroxo hemiacetal is suggested to decay via a process by which the proximal oxygen atom removes the 1␤-hydrogen, resulting in aromatization of the steroid A ring and formic acid release (11) . Model reaction studies have suggested that formation of the 2,3-enol is a prerequisite for aromatization. A homology model of the aromatase enzyme suggests the presence of an aspartic acid residue near the 2␤-hydrogen and lysine or histidine residues near the 3-ketone of androstenedione (12) . The orientation of these residues is supportive of an enzyme acid-base-catalyzed enolization process to selectively remove the 2␤-hydrogen.
Recently, our laboratory has employed computational chemistry approaches to unravel the mysterious third step of aromatase catalysis (13) . Recent advances in computational chemistry, including density functional theory alone or in combination with molecular mechanical methods, have provided better tools that enable study of the active species in their native protein environment, such as the cytochrome P450 oxidant Compound I (14) . A model system of the cytochrome P450 active site and truncated steroid substrates has been studied using density functional theory calculations and ab initio molecular dynamics. Analysis for the reduced ferrous dioxygen (peroxy) intermediate suggests that 1␤-hydrogen atom abstraction by the proximal oxygen of the peroxo hemiacetal intermediates encounters a high energetic barrier (Ͼ60 kcal/mol) that is enzymatically inaccessible. Also, the resulting species do not directly fragment to the experimentally observed formic acid and aromatized steroid products. A novel, alternative mechanism was examined, in which the widely accepted cytochrome P450 oxidant Compound I, the iron oxene catalytic intermediate (Fig. 2B) , abstracts the 1␤-hydrogen atom initiating the aromatization and deformylation cascade. The steroid models that contain the 2,3-enol moiety have a strikingly low barrier for 1␤-hydrogen atom abstraction (Ͻ7 kcal/mol) due to the ability of the enolized A ring to delocalize the impending radical. The transition states containing the 2,3-enol moiety and the 19-gem diol decay directly to the aromatized product, formic acid, and the aqua-bound model cytochrome P450 enzyme. Analysis of the reaction vectors indicate that the second hydrogen transfer occurs with a concerted, nonsynchronous mechanism without an energetic barrier. Thus, these calculations support a final catalytic step of aromatase involving the cytochrome P450 oxene intermediate, 1␤-hydrogen atom abstraction, and release of formic acid (Fig. 2) .
B. Aromatase gene expression
Over the past two decades, knowledge of the biochemistry, molecular biology, and regulation of aromatase has increased greatly. The aromatase gene, designated CYP19, en-
FIG. 1. Aromatase enzyme reaction
codes the cytochrome P450 arom , and this gene is located on chromosome 15q21.1. The coding region is approximately 30 kb in size, and the regulatory region is approximately 93 kb (9, 15) . The aromatase gene consists of 10 exons, and its full-length cDNA of 3.4 kb encodes for a protein of 503 amino acids. The aromatase protein is a glycosylated cytochrome P450 protein with a molecular mass of approximately 58,000 Da (16) . The regulation of aromatase is complex in various tissues, and several tissue-specific promoter regions have been identified upstream from the CYP19 gene (9, 17, 18) . These tissue-specific promoters include promoter PI.1, PI.3, PI.4, PI.6, PI.7, and PII (Fig. 3) . Promoter PI.1 is the major promoter used in placental tissues and is the farthest upstream. The PII promoter is used in the ovary and in breast cancer tissues, and it contains a cAMP response element. Promoters PI.3, PI.4, PI.6, and PI.7 are the promoters used in extraglandular sites. Promoter PI.4 is the primary promoter used in normal adipose tissue and is responsive to glucocorticoids and cytokines such as IL-1␤, IL-6, and TNF␣. Promoter PI.3 is also present in adipose tissues such as normal breast tissue and is elevated in breast cancer tissues.
C. Aromatase in breast cancer tissues
Aromatase is found in breast tissue, and the importance of intratumoral aromatase and local estrogen production is being unraveled (6, 19, 20) . Aromatase has been measured in the stromal cell component of normal breast and breast tumors, but the enzyme has also been detected in the breast epithelial cells in vitro (5, 8, 20 -22) . Furthermore, expression of aromatase is highest in or near breast tumor sites (8, 20) . The exact cellular location(s) of aromatase must await more rigorous analysis by several laboratories with a new monoclonal antibody now being developed and evaluated (23) .
The increased expression of aromatase cytochrome P450 arom observed in breast cancer tissues is associated with a switch in the major promoter region used in gene expression, with promoter PII being the predominant promoter used in breast cancer tissues (24) . As a result of the use of the alternate promoter, the regulation of estrogen biosynthesis switches from one controlled primarily by glucocorticoids and cytokines to a promoter regulated through cAMP-mediated pathways (24) . Prostaglandin E 2 (PGE 2 ) increases intracellular cAMP levels and stimulates estrogen biosynthesis (24) , whereas other autocrine factors such as IL-1␤ do not appear to act via PGE 2 (25) .
Local production of PGE 2 via the cyclooxygenase isozymes (constitutive COX-1 isozyme and inducible COX-2 isozyme) can influence estrogen biosynthesis and estrogendependent breast cancer. This biochemical mechanism may explain epidemiological observations of the beneficial effects of nonsteroidal antiinflammatory drugs (NSAIDs) on breast cancer (26 -29) . Investigations using human breast cancer patient specimens demonstrated a strong linear correlation between CYP19 expression and the sum of COX-1 and COX-2 expression (30) . Gene expression analysis for CYP19, COX-1, and COX-2 were performed in 20 human breast cancer specimens and in five normal control breast tissue samples. A positive correlation was observed between CYP19 expression and the greater extent of breast cancer cellularity (Fig.  4A ), in agreement with literature reports showing that aromatase levels were higher in tumors than in normal tissue. Furthermore, a positive linear correlation was observed between COX-2 expression breast cancer cellularity in each sample. Linear regression analysis using a bivariate model shows a strong linear association between CYP19 expression and the sum of COX-1 and COX-2 expression (Fig. 4B) . Similar correlations between CYP19 expression and COX-2 expression in breast cancer patient specimens have been confirmed in other laboratories (31) . This significant relationship between the aromatase and COX enzyme systems suggests that autocrine and paracrine mechanisms may be involved in hormone-dependent breast cancer development via growth stimulation from local estrogen biosynthesis. In human breast stromal cells, PGE 2 acts via two G protein-coupled receptors, EP 1 and EP 2 receptors, to stimulate aromatase gene expression via protein kinase A and protein kinase C signaling pathways (32) . NSAIDs and COX-1-and COX-2-selective inhibitors produce dose-dependent decreases in aromatase activity in breast cancer tissues ( Fig. 5) (33, 34) . Real time PCR analysis of aromatase gene expression showed a significant decrease in mRNA levels by these agents, and the effect of COX inhibitors on aromatase expression occurs through suppression at the tissue-specific promoters PI.3, PI.4, and PII. This significant relationship between the aromatase and COX enzyme systems suggests that autocrine and paracrine mechanisms may be involved in hormonedependent breast cancer development via growth stimulation from local estrogen biosynthesis (Fig. 6 ).
III. Development of Aromatase Inhibitors
Two primary approaches have been developed to reduce the growth-stimulatory effects of estrogens in breast cancer: 1) interfering with the ability of estrogen to bind to its receptor; and 2) decreasing circulating levels of estrogen. Antiestrogens compete for binding to the estrogen receptors and reduce the number of receptors available for binding to endogenous estrogen. This approach has proven effective as an anticancer strategy (35, 36) and has led to the development of efficacious antiestrogens, such as the drug tamoxifen, that exhibit minimal toxicity. Inhibition of aromatase is the second approach for reducing growth-stimulatory effects of estrogens. Effective aromatase inhibitors have been developed as therapeutic agents for controlling estrogen-dependent breast cancer. Investigations on the development of aromatase inhibitors began in the 1970s and have expanded greatly in the past three decades. Research summaries of aromatase inhibitors have been presented at international aromatase conferences (37) (38) (39) (40) (41) , and several reviews have also been published (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) .
A. Steroidal inhibitors

Competitive enzyme inhibitors.
Investigations on the development of aromatase inhibitors began with the synthesis and biochemical evaluation of competitive inhibitors (52) (53) (54) . Competitive inhibitors are molecules that compete with the substrate androstenedione for noncovalent binding to the active site of the enzyme to decrease the amount of product formed. The term "apparent K i " represents the equilibrium constant for the reversible binding of the enzyme and the inhibitor. The values are used in comparisons of inhibitors, and the smaller the K i value, the better the inhibitor. Steroidal inhibitors that have been developed to date build upon this basic androstenedione nucleus and incorporate chemical substituents at varying positions on the steroid (Fig. 7) . These inhibitors bind to the aromatase cytochrome P450 enzyme in the same manner as the substrate androstenedione. Initial structure-activity relationships were developed with these early investigations on competitive aromatase inhibitors. In summary, effective inhibition is observed with an androstane steroid molecule possessing an A/B trans ring junction, a ketone functionality at the C-3 position, unsaturation in the steroid nucleus (4-ene, 4,6-diene, or 1,4,6-diene functions), and either a 17-ketone or 17␣-hydroxyl moiety.
A limited number of effective inhibitors with substituents on the A ring have been reported. Several steroidal aromatase inhibitors contain modifications at the C-4 position, with 4-hydroxyandrostenedione being the prototype agent. Initially, 4-hydroxyandrostenedione was thought to be a competitive inhibitor with an apparent K i of approximately 170 nm, but the compound was later shown to produce enzyme-mediated inactivation. The spacial requirements of the A ring for binding of the steroidal inhibitor to aromatase are rather restrictive, permitting only small structural modifications to be made. Incorporation of the polar hydroxyl group at C-4 enhances inhibitory activity. 1-Methylandrosta-1,4-diene-3,17-dione is a potent inhibitor of aromatase in vitro and in vivo (55) ; on the other hand, bulky substitutents at the 1␣-position are poor inhibitors (54) .
Extensive structural modifications may be made on the B ring of the steroid nucleus. Bulky substitutions at the C-7 position of the B ring have provided several very potent aromatase inhibitors (54) . One of the more potent inhibitors, 7␣-(4Ј-amino)phenylthio-4-androstene-3,17-dione with an apparent K i of 18 nm, demonstrated effectiveness in inhibiting aromatase in cell cultures and in treating hormonedependent rat mammary tumors (56 -58) . Evaluation of various substituted aromatic analogs of 7␣-(4Ј-amino)phenylthio-4-androstene-3,17-dione provided no correlation between the electronic character of the substituents and inhibitory activity. Investigations of various 7-substituted androsta-4,6-diene-3,17-dione derivatives suggest that only those derivatives that can project the 7-aryl substitutent into the 7␣-pocket are effective inhibitors (59) . Several compounds with substituents at the C-6 position have been described which exhibit irreversible inhibition; these are discussed in a later section. Overall, the most effective B ringmodified aromatase inhibitors are those with 7␣-aryl derivatives, with several analogs having 2-10 times greater affinity for the enzyme than the substrate. These results suggest that additional interactions occur between the phenyl ring at the 7␣-position and amino acids at or near the enzymatic site of aromatase, resulting in enhanced affinity.
The other position of androstenedione that has received considerable investigation and has resulted in effective inhibitors is the C-19 methyl position, the site of enzymatic oxidation. Competitive inhibitors have been designed to enhance affinity through noncovalent binding of a heteroatom at C-19 with the heme iron of the cytochrome P450 arom . 19-Substituted aromatase inhibitors include thiiranes and oxiranes (60, 61) , epoxysteroids (62) , and thiol and amino analogs (63, 64) . The 19R-isomers of the thiiranes and oxiranes were potent inhibitors with apparent K i values ranging from 1-7 nm, showed affinity 36-to 80-fold greater than the corresponding 19S-isomers, and demonstrated binding to the heme iron in spectroscopic studies. Unique 2,19-bridged androstenediones have also been reported (65) (66) (67) . These A ring-bridged steroids consist of both five-membered and six-membered ring analogs containing carbon, oxygen, nitrogen, or sulfur atoms. Several of these compounds exhibited apparent K i values in the low nanomolar range and demonstrated tight-binding competitive inhibition. Thus, effective inhibitors have been prepared with geometrically small functionalities at the C-19 position, suggesting that the enzyme active site can accommodate small changes in structure.
Mechanism-based enzyme inhibitors.
A mechanism-based inhibitor is an inhibitor that mimics the substrate, is converted by the enzyme to a reactive intermediate, and results in the inactivation of the enzyme. The term "mechanism-based" is used because the inhibitor contains a chemical functionality that is acted upon by the enzyme during the normal catalytic process. A mechanism-based inhibitor produces time-dependent inactivation of the enzyme only in the presence of catalytically active enzyme; omission of a cofactor, such as NADPH, does not produce inactivation. Other terms that are used for these inhibitors are "enzyme-activated irreversible inhibitors," "suicide substrates," and "suicide inactivators." Several mechanism-based aromatase inhibitors, structurally related to the natural substrate androstenedione (Fig. 8) , are initially recognized by the aromatase enzyme as alternate substrates and are then transformed (through an NADPHdependent mechanism) to reactive intermediates, which bind irreversibly to the enzyme and produce inactivation. Inactivation kinetic values are determined from plots of the half-time of inactivation, i.e., the time required to decrease the enzymatic activity by 50%, vs. the reciprocal of the inhibitor concentration. The y-intercept of the resulting line is the half-time of inactivation at infinite inhibitor concentration (t 1/2 ) and the rate of inactivation, apparent k inact , is equal to 0.693/t 1/2 . The most effective mechanism-based inhibitors exhibit short half-times of inactivation (t 1/2 ) and rapid rates of inactivation. Mechanism-based inhibitors have distinct advantages in drug design, because these inhibitors are highly enzyme specific, produce prolonged inhibition, and often exhibit minimal toxicities.
The first compound designed as a mechanism-based inhibitor of aromatase was 10-propargyl-4-estrene-3,17-dione (MDL 18,962); it was synthesized and studied independently by three research groups (68 -70) . MDL 18,962 has an electron-rich alkynyl function on the C-19 carbon atom, the site of aromatase-mediated oxidation of the substrate, and is an effective inhibitor in vitro and in vivo (71) (72) (73) (74) . In biochemical assays, MDL 18,962 exhibited a half-time of inactivation at infinite inhibitor concentration (t 1/2 ) of 10.41 min and an apparent k inact of 1.11 ϫ 10 Ϫ3 sec Ϫ1 . Although the identity of the reactive intermediate formed is not known, an oxirene and a Michael acceptor have been suggested.
A larger number of mechanism-based inhibitors have developed from more detailed biochemical investigations of several inhibitors originally thought to be competitive inhibitors. These inhibitors can be grouped into the general categories of 4-substituted androst-4-ene-3,17-diones, substituted androsta-1,4-diene-3,17-diones, and 6-methylene-or 6-oxo-androst-4-ene-3,17-diones.
4-Hydroxy-4-androstene-3,17-dione (4-hydroxyandrostenedione, formestane), originally thought to be a competitive inhibitor, produces enzyme-mediated inactivation (75) . In enzyme assays, 4-hydroxyandrostenedione exhibited a halftime of inactivation at infinite inhibitor concentration (t 1/2 ) of 2.57 min and an apparent k inact of 4.50 ϫ 10 Ϫ3 sec Ϫ1 . In vivo, formestane inhibits reproductive processes (76) and causes regression of hormone-dependent mammary rat tumors (77, 78) . Formestane is effective and well tolerated in the treatment of advanced breast cancer in postmenopausal women (79, 80) ; however, extensive first-pass metabolism of this agent in the liver necessitates im administration and limits its use (81-83).
Numerous androsta-1,4-diene-3,17-diones have been prepared and have demonstrated mechanism-based or enzymemediated inactivation of aromatase in vitro. Androsta-1,4-diene-3,17-dione and androsta-1,4,6-triene-3,17-dione were initially thought to be competitive inhibitors, but further examination of the biochemistry of these inhibitors revealed that these compounds demonstrated inactivation of aromatase only in the presence of cofactors (84, 85) . Introduction of substituents at the 7␣-position of both androsta-1,4-diene-3,17-dione and androsta-1,4,6-triene-3,17-dione have resulted in very effective mechanismbased inhibitors of aromatase (57, 86 -89) . 7␣-(4Ј-Amino) phenylthioandrosta-1,4-diene-3,17-dione has high affinity for aromatase, with an apparent K i of 9.9 nm, and has the most rapid rate of inactivation reported to date with a half-time of inactivation (t 1/2 ) of 1.38 min and an apparent k inact of 8.40 ϫ 10 Ϫ3 sec Ϫ1 . More metabolically stable inhibitors were synthesized by replacing the thioether linkage at the 7␣-position with a carbon-carbon linkage. The best inactivator of the series was the 7␣-phenpropylandrosta-1,4-diene-3,17-dione, which exhibited a t 1/2 of 6.08 min and an apparent k inact of 1.90 ϫ 10 Ϫ3 sec Ϫ1 . An exocyclic double bond at the C-6 carbon atom results in 6-methyleneandrost-1,4-diene-3,17-dione (exemestane), which produces aromatase inactivation in vitro and causes regression of hormone-dependent mammary rat tumors (90 -92) . Exemestane is a potent inhibitor of both human placental aromatase with apparent K i of 26 nm, a t 1/2 of 13.9 min, and an apparent k inact of 8.30 ϫ 10 Ϫ4 sec Ϫ1 . Exemestane, when administered sc or orally, inhibits rat ovarian aromatase (ED 50 of 1.8 and 3.7 mg/kg, respectively) (90, 93) .
Despite the large number of effective mechanism-based or enzyme-activated inhibitors that have been prepared, no detailed mechanism(s) of action have been identified. All agents produce time-dependent inactivation of aromatase activity only when incubated with catalytically active enzyme, no inactivation is observed in the absence of cofactors such as NADPH, and coincubations with the substrate androstenedione decrease the rates of inactivation. Investigations of radiolabeled mechanism-based inhibitors, [ 125 I]-7␣-(4Ј-iodo)phenylthioandrosta-1,4-diene-3,17-dione and [
14 C]-MDL 18,962, provided the first evidence of irreversible binding of these inhibitors to the aromatase protein (94) . Radiolabeled inhibitors were incubated with purified reconstituted aromatase preparations and NADPH, and the cytochrome P450 arom protein was isolated by gel chromatography after the incubation. Subsequent treatments of the cytochrome P450 arom protein fractions by precipitation, extensive washings, and SDS-PAGE demonstrated that the radioactive inhibitors remain bound to the cytochrome P450 arom protein. Thus, the mechanism-based inactivation that occurs is due to irreversible, covalent binding of the inhibitors to the enzyme protein. The exact nature of the covalent bound(s), the chemical structures of the bound inhibitors, and the amino acids involved are yet to be elucidated. Additionally, the question of whether the inhibitors are oxidized at the C-19 position in a manner similar to the substrate androstenedione before irreversible binding and inactivation remains to be answered. 
B. Nonsteroidal inhibitors
First-and second-generation inhibitors.
Nonsteroidal aromatase inhibitors possess a heteroatom as a common chemical feature and interfere with steroid hydroxylations by the binding of this heteroatom with the heme iron of the cytochrome P450s (Fig. 9) . Initial nonsteroidal inhibitors were less enzyme specific and inhibited, to varying degrees, other cytochrome P450-mediated hydroxylations of steroidogenesis. Aminoglutethimide was the prototype for nonsteroidal aromatase inhibitors (95) . Aminoglutethimide was originally an antiepileptic agent that was removed from the market due to serious side effects. Aminoglutethimide inhibited cytochrome P450 SCC and other enzyme pathways but was more selective for cytochrome P450 arom . The racemic mixture (dlaminoglutethimide) inhibits aromatase with an apparent K i of 700 nm. The d-aminoglutethimide stereoisomer is 20-fold more potent than the l-aminoglutethimide stereoisomer.
Because aminoglutethimide was the first aromatase inhibitor to be studied in patients, it is referred to as the firstgeneration aromatase inhibitor. Aminoglutethimide has been used in the clinics with some success to treat patients with advanced breast cancer, but it must be administered with corticosteroid due to the inhibitory effects on cortisol and aldosterone biosynthesis (95, 96) . Although effective at decreasing aromatization, it also inhibited a number of other steroidogenic CYP-450 enzymes, which resulted in significant toxicity. The imidazole compound fadrazole is a potent, competitive inhibitor of aromatase both in vitro and in vivo (97) . Fadrazole, referred to as a "second-generation inhibitor," is more selective than aminoglutethimide, and its inhibitory activity is 700 times more potent. Clinical studies using fadrazole proved this nonsteroidal inhibitor is effective in the treatment of some postmenopausal women with advanced breast cancer. Both partial and complete responses were observed upon treatment with fadrazole. However, this compound still has some nonselective inhibitory activity with respect to aldosterone, progesterone, and corticosterone biosynthesis. The apparent K i for the racemate of fadrazole in human placental microsomes is 1.6 nm, and the (Ϫ)-S isomer is equipotent to the racemate whereas the (ϩ)-R isomer has a lower inhibitory activity with an apparent K i of 39 nm (98).
Third-generation triazole inhibitors.
Several nonsteroidal aromatase inhibitors containing a triazole ring have been successfully developed. Vorozole potently inhibits aromatase in numerous in vitro systems, with an apparent K i of 1.3 nm in human placental microsomes (99) . The racemate has been tested thoroughly, but it is known that the (ϩ)-S isomer is 36 times more potent than the (Ϫ)-R isomer (100). Regression of tumors in a hormone-dependent rat tumor model has been demonstrated with various doses of vorozole. Another triazole analog is anastrozole, which is an achiral triazole derivative (101) . Anastrozole is a potent aromatase inhibitor with an IC 50 of 15 nm in human placental microsomes. In vitro, anastrozole has no effect on numerous other P450 enzymes such as, P450 SCC , 11␤-hydroxylase, 18-hydroxylase, 17␣-hydroxylase, and lanosterol-14␣-demethylase. In vivo studies in monkeys showed that anastrozole, at a dose of less than 0.2 mg/kg⅐d, reduced peripheral aromatase activity by 50 -60% (101). The third triazole derivative, letrozole, is a potent inhibitor of aromatase with an IC 50 of 11.5 nm in human placental microsomes (102) . In in vitro studies, letrozole has no effect on the biosynthesis of other steroids such as aldosterone, progesterone, or corticosterone. In vivo, letrozole was determined to be orally active and to cause regression of tumors in the 7,12-dimethylbenz(a)anthracene hormone-dependent rat tumor model, and it demonstrated aromatase inhibition in patients (103) . A higher degree of specificity has been reached with the new generation of triazole derivatives (letrozole and anastrozole). These newer agents are 100-3000 times more active than aminoglutethimide, and all inhibit whole-body aromatization by greater than 96%.
Flavonoid derivatives as inhibitors.
Flavonoids are plant natural products present in many food sources, including fruits, vegetables, legumes, and whole grains. The class of flavonoids encompasses flavones, isoflavones, flavanones, and flavonols, each possessing the benzopyranone ring system as the common chemical scaffold. Considerable interest in flavonoids in breast cancer has been stimulated by the hypothesis that these natural products, present in soy and in rye flour, are dietary factors that may be responsible for the lower incidence of breast cancer in women from certain regions of the world (104, 105) . Several flavonoids demonstrate inhibitory activities of the aromatase enzyme, thus lowering estrogen biosynthesis and circulating estrogen levels ( Fig. 10)  (104, 106 -111 ). However, these natural products demon- (106) , with 7,8-benzoflavone displacing androstenedione from the aromatase active site and inducing a spectrum consistent with the low-spin state of iron. Reduction of the flavone 4-keto group was detrimental to aromatase inhibition by these compounds (107) . Based on data obtained from site-directed mutagenesis studies and ligand docking into a homology model of the aromatase protein, a binding orientation was predicted in which the A and C rings of the flavone mimic the C and D rings of the steroid substrate, respectively. The 2-phenyl substituent is oriented in a region similar to that occupied by the A ring of the steroid. This analysis places the flavone 4-keto functionality in the same position as the steroid 19-angular methyl group with respect to the heme iron (110) .
Medicinal chemistry approaches to develop synthetic flavonoids, chromone, or xanthone analogs with enhanced aromatase inhibitory activity have identified more selective and/or more potent agents for future development (112) (113) (114) . Generally, flavones and flavanones have higher aromatase inhibitory activity than isoflavones (Fig. 10) (110, 115) . This large difference in potency is the likely reason why there has been little effort to develop aromatase inhibitors on an isoflavone scaffold. On the other hand, we envisioned introduction of the proper functional groups on the isoflavone core could result in the desired aromatase activity. As a proof of principle, a 2-(4-pyridylmethyl)thio functionality was introduced onto the isoflavone nucleus (Fig. 10) , and this isoflavone modification afforded a 160-fold enhancement in potency compared with the natural product, biochanin A (116). In human placental microsomal assays, the synthetic pyridyl isoflavone analog, 3-phenyl-7-(phenylmethoxy)-2-[(4Ј-pyridylmethyl)thio]-4H-1-benzopyran-4-one, exhibited an IC 50 value of approximately 210 nm and an apparent K i value of 220 nm.
IV. Aromatase Inhibitors in Breast Cancer
A. First-and second-generation aromatase inhibitors
1. Aminoglutethimide. Aminoglutethimide was the first of these inhibitors evaluated in clinical studies for treatment of hormone-dependent breast cancer (117). Santen et al. (118) extensively evaluated the kinetic and hormonal effects of aminoglutethimide in breast cancer and first proposed aromatase inhibition as the primary mechanism of action of aminoglutethimide therapy. Numerous clinical trials performed since the early 1980s have demonstrated the clinical efficacy of combination therapy of aminoglutethimide with corticosteroid replacement (96, 119) in treatment of hormonedependent breast cancer. However, side effects of lethargy, ataxia, and morbilliform skin rash and the development of more potent aromatase inhibitors resulted in cessation of further development of aminoglutethimide for breast cancer.
4-Hydroxyandrostenedione.
The steroidal inhibitor 4-hydroxyandrostenedione, generic name of formestane, was extensively evaluated in clinical trials and was the first aromatase inhibitor approved for general use in Europe. In a series of clinical studies (120), 4-hydroxyandrostenedione treatment in unselected postmenopausal breast cancer patients with either weekly or biweekly im injections resulted in 26% of patients experiencing complete or partial responses and another 25% exhibiting disease stabilization. Decreased serum estrogen levels have been observed in postmenopausal breast cancer patients. The drug is extremely well tolerated, and only a low percentage (13%) of patients experienced pain and/or inflammation at the injection site. Because 4-hydroxyandrostenedione (formestane) was the second aromatase inhibitor to be studied in patients, it is referred to as a second-generation aromatase inhibitor.
B. Third-generation aromatase inhibitors
The third-generation aromatase inhibitors include the nonsteroidal inhibitors anastrozole and letrozole and the steroidal inhibitor exemestane. These third-generation aromatase inhibitors have received extensive clinical evaluations (121-126).
1. Anastrozole. Anastrozole (Arimidex; Astra-Zeneca, London, UK) is a potent nonsteroidal aromatase inhibitor in patients, decreasing plasma estradiol levels in a dose-dependent manner and producing approximately 97% inhibition of estrogen biosynthesis at the dose of 1 mg/d (127) . Anastrozole was well tolerated in two large, Phase III trials of anastrozole vs. megestrol acetate in patients who progressed on tamoxifen, and the combined analysis demonstrated a clinically significant advantage over megestrol acetate (128 -130) . Two randomized, double-blind studies demonstrated that anastrozole (1 mg daily) was more effective than tamoxifen (20 mg daily) as first-line therapy in postmenopausal women with advanced breast cancer (131) (132) (133) . Anastrozole at the recommended therapeutic dose of 1 mg once daily effectively suppressed total-body aromatization, with a mean percentage inhibition of 97.3%, and suppressed plasma estrone and estradiol levels by 81-85% in postmenopausal women with metastatic breast cancer (134) . In clinical trials with postmenopausal women, no changes were detected in levels of androgens, an increase in the gonadotropins LH and FSH was observed over time, and a decrease in SHBG was also detected (135).
2.
Letrozole. Letrozole (Femara; Novartis, Basel, Switzerland) is a potent nonsteroidal aromatase inhibitor that produces approximately 99% inhibition of estrogen biosynthesis at the dose of 2.5 mg/d in patients (136) . Clinical studies, involving postmenopausal women with advanced breast cancer who have had numerous previous endocrine treatments, showed that letrozole produced either a partial response or stabilization of disease in about 40% of the women (137, 138).
Letrozole is also well tolerated, causes a marked decrease in serum and urine estrogen levels, and has little effect on other endocrine factors. In clinical trials with postmenopausal women, plasma levels of androgens were unchanged with letrozole treatment, and increases in LH, FSH, and SHBG were detected over time (139) . A multicenter, randomized, double-blind study in advanced breast cancer reported letrozole more effective than tamoxifen in response rate, clinical benefit, time to progression, and time to treatment failure (140) . Letrozole at the recommended therapeutic dose of 2.5 mg once daily effectively suppressed total-body aromatization, with a mean percentage inhibition of greater than 99.1%, and suppressed plasma estrone and estradiol levels by 84 -88% in postmenopausal women with metastatic breast cancer (141).
3. Exemestane. Exemestane (Aromasin; Pfizer, New York, NY) is a potent steroidal inhibitor of human placental aromatase, and a single oral dose of 25 mg exemestane was found to cause a long-lasting reduction in plasma and urinary estrogen levels. Maximal suppression of circulating estrogens occurred 2-3 d after dosing and persisted for 4 -5 d (142) . The lengthy duration of estrogen suppression is thought to be related to the irreversible nature of the drug-enzyme interaction rather than pharmacokinetic properties of the compound. Exemestane is also well tolerated, causes a marked decrease in serum and urine estrogen levels, and has no effect on other endocrine factors (142) (143) (144) (145) (146) . Increased doses of exemestane can lead to suppression of SHBG (147, 148) . Exemestane was shown to inhibit peripheral aromatase by 97-98% (144, 149) . Table 1 compares the inhibitory activities in vitro and in vivo of aromatase inhibitors that have been evaluated clinically. As described earlier, anastrozole and letrozole are both nonsteroidal competitive inhibitors of aromatase, whereas exemestane is a mechanism-based inhibitor. Investigations of these therapeutic agents in cell lines expressing high levels of aromatase, such as JEG-3 and JAr choriocarcinoma cells, have examined the impact of these inhibition characteristics on the residual in vitro aromatase activity and protein levels. Several mechanism-based aromatase inhibitors produce prolonged suppression of aromatase catalytic activity for up to 48 h in cells following short drug exposure (72, 94, 150) . On the other hand, the nonsteroidal inhibitor aminoglutethimide resulted in elevated levels of aromatase enzyme activity under similar conditions, possibly due to enzyme stabilization (150) . In a study comparing letrozole (3 nm), exemestane (20 nm), anastrozole (40 nm), and aminoglutethimide (10 nm), aromatase activity returned to control levels immediately after letrozole exposure and increased by about 60, 30, and 20% after 4, 24, and 48 h, respectively. After preincubation with anastrozole or aminoglutethimide, cellular aromatase also increased. On the other hand, suppression of aromatase activity was maintained for approximately 24 -48 h after the removal of exemestane (151) . There was no increase in the aromatase protein level in either experiment. In a study with cultured fibroblasts from mammary adipose tissue preincubated with an antiaromatase agent for 18 h, removal of aminoglutethimide or anastrozole elicited up to 40% increases in aromatase activity, whereas preincubation with exemestane resulted in a marked suppression (152) .
C. Clinical studies
The third-generation aromatase inhibitors are approved in the United States for the treatment of postmenopausal women with metastatic estrogen-dependent breast cancer. Both anastrozole and letrozole were more effective than tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer (131) (132) (133) 153) . Exemestane has also shown enhanced efficacy over tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer (154) . In these clinical studies, the aromatase inhibitors demonstrated improved clinical efficacy in primary endpoints of objective response rates (complete response, partial response, or disease stabilization), time to progression, and time to treatment failure. Patients positive for estrogen receptor (estrogen receptor positive) and/or progesterone receptor (progesterone receptor positive) had better response rates when treated with aromatase inhibitors than the patients treated with tamoxifen. Overall, the third-generation aromatase inhibitors are well tolerated in these clinical trials of postmenopausal women with hormone-dependent metastatic breast cancer.
Current clinical studies of aromatase inhibitors are focusing on the use of the agents in the adjuvant setting for the treatment of early breast cancer (121, 125, 155, 156) . These studies assess the effectiveness of aromatase inhibitors following tamoxifen, of aromatase inhibitors alone, and/or of the combination of aromatase inhibitors and tamoxifen in adjuvant therapy. Table 2 summarizes the key adjuvant trials for the third-generation aromatase inhibitors. Early results from three randomized, adjuvant Phase III clinical trials have recently been published. The largest of these trials, Anastrozole, Tamoxifen Alone, or in Combination, recruited 9366 postmenopausal women with early breast cancer, and the patients were randomized into one of the three treatment arms for 5 yr. After a median follow-up of 47 months, the anastrozole arm of the study resulted in statistically significant reduction in breast cancer events and improvement of disease-free survival (157, 158) . No differences in disease-free survival were observed between the tamoxifen-alone arm and the combination arm. The MA-17 trial recruited 5187 postmenopausal women who had taken tamoxifen for 5 yr, and these patients were randomized into two treatment arms of letrozole or placebo for an additional 5 yr. After a median follow-up of 2.4 yr, the letrozole-treated patients had a significant reduction of breast cancer events (159) . At this analysis, the data safety and monitoring committee for the MA-17 study recommended that the trial be halted early and the participants informed of the positive results. The Intergroup Exemestane Study enrolled 4742 postmenopausal women who had taken tamoxifen for 2 or 3 yr, and these patients were randomized into two treatment arms of tamoxifen for a total of 5 yr or exemestane to complete the 5-yr hormonal therapy. Exemestane therapy after 2-3 yr of tamoxifen therapy significantly reduced breast cancer recurrence and contralateral breast cancer as compared with the standard 5 yr of tamoxifen treatment (160) . Based on the results of these multiple, large randomized trials, the American Society of Clinical Oncology technology assessment panel (161) recommends that the "optimal adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen." These multiple, large randomized trials also enabled a more thorough analysis of the tolerability and adverse events of the aromatase inhibitors. In general, patients receiving aromatase inhibitors experienced less gynecological symptoms such as endometrial cancer, vaginal bleeding, and vaginal discharges. Fewer cerebrovascular events and venous thromboembolic events were also observed with patients receiving aromatase inhibitors. No information is yet available on the effects of aromatase inhibitors on serum lipid levels, cardiovascular disease, and coronary heart disease risk. On the other hand, musculoskeletal effects and bone toxicity are associated with aromatase inhibitors. The percentages of musculoskeletal effects, which include increased arthritis, arthralgia, and/or myalgia, were small but showed statistically significant increases with aromatase inhibitors compared with tamoxifen. All three aromatase inhibitors were associated with increased fractures when compared with tamoxifen or placebo. The Anastrozole, Tamoxifen Alone, or in Combination trial reported a 7.1% fracture incidence in the anastrozole arm vs. tamoxifen at 4.4% (157, 158) . In the MA-17 study, fractures in the letrozole-treated patients were 3.6% compared with 2.9% in placebo, after 2 or 3 yr of prior tamoxifen treatment (159) . Exemestane was associated with osteoporosis and/or increased fractures (7.41%) when compared with tamoxifen (5.7%) in the Intergroup Exemestane Study trial. Baseline bone mineral density evaluations and potential bisphosphonate therapy are recommended (161) .
Other ongoing clinical studies are designed to compare the various aromatase inhibitors and/or combination therapies in early-stage breast cancer or in the chemoprevention setting. For example, MA-27 is a Phase III adjuvant trial in postmenopausal women with primary breast cancer comparing exemestane with anastrozole, with or without celecoxib, a COX-2 inhibitor. The potential for aromatase inhibitors in the chemoprevention setting in women with increased risk for the development of breast cancer is also being considered. In preclinical models, aromatase inhibitors reduce tumor formation in the carcinogen-induced rat mammary tumor studies (162) (163) (164) (165) . The International Breast Cancer Intervention Study II will compare anastrozole vs. placebo in a prevention study, and the accompanying Ductal Carcinoma in Situ Study will compare tamoxifen vs. anastrozole in women with locally excised ductal carcinoma in situ (166) . A Canadian breast cancer prevention study, NCIC MAP3, is a three-arm study of placebo vs. exemestane vs. exemestane and celecoxib (166) . Important endpoints in such trials may include not only reduction in tumor incidence but also may examine effects of aromatase inhibitors on bone mineral density and serum lipid levels.
V. Conclusions
Aromatase inhibitors, both steroidal and nonsteroidal agents, have been shown to be useful for the treatment of breast cancer. These compounds work by preventing the synthesis of estrogens in the body. Aromatase inhibitors appear to be more effective in postmenopausal women than in premenopausal women due to the fact that the major source of estrogen biosynthesis in postmenopausal women is adipose tissue. Over the years, both steroidal and nonsteroidal inhibitors have developed into very potent compounds that are highly selective for aromatase vs. other steroidogenic cytochrome P450 enzymes. The potent, selective and orally-active third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, were initially approved for clinical use as endocrine therapy in postmenopausal patients failing antiestrogen therapy alone or multiple hormonal therapies. More recent clinical studies have shown that these aromatase inhibitors are more effective than tamoxifen in postmenopausal patients with metastatic breast cancer, and these agents are the approved therapy for the treatment of postmenopausal women with metastatic estrogen-dependent breast cancer. Furthermore, the third-generation aromatase inhibitors are now being studied in the adjuvant setting either alone or in combination with other agents. Based on the results of these multiple, large randomized trials, the American Society of Clinical Oncology panel recommends adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer with an aromatase inhibitor as initial therapy or after treatment with tamoxifen.
